Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs US Foods Holding Corp. Common Stock (USFD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs US Foods Holding Corp. Common Stock — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while US Foods Holding Corp. Common Stock trades at $98.45 (market cap $21.18B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 2.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is more actively traded (1,441,031 versus 1,065,315). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and US Foods Holding Corp. Common Stock for 6 Days on average.
| SYRE | USFD | |
|---|---|---|
Market Cap | $7.52B | $21.18B |
Volume | 1,441,031 | 1,065,315 |
Sector | Health | Consumer Staples |
52-Week High | $108.92 | $110.94 |
52-Week Low | $22.18 | $70.05 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.52B | $26.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
US Foods (USFD) trades at $97.91, showing modest daily gains of 0.21%. The stock maintains a bullish technical trend with strong moving average support and trades near key resistance at $98. Fundamentally, the company demonstrates solid revenue growth with $39.42B in 2025 sales and improving profitability, though net margins remain thin at 1.81%. Recent business developments include new product launches and conference participation, signaling ongoing operational momentum.
The outlook remains positive with analyst consensus strongly favoring Buy ratings (73%) and a $117 price target suggesting 19% upside. Key opportunities include margin expansion and market share gains, while risks involve competitive pressures and execution challenges in a low-margin industry. The combination of technical strength, fundamental improvement, and Wall Street support positions USFD favorably for continued growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About US Foods Holding Corp. Common Stock
US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →
